FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1984152194> ?p ?o ?g. }

• W1984152194 endingPage "15985" @default.
• W1984152194 startingPage "15980" @default.
• W1984152194 abstract "A 150-kDa protein that inhibits phospholipase D (PLD) activity stimulated by ADP-ribosylation factor and phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) was previously purified from rat brain. The sequences of peptides derived from the purified PLD inhibitor now identify it as synaptojanin, a nerve terminal protein that has been implicated in the endocytosis of fused synaptic vesicles and shown to be a member of the inositol polyphosphate 5-phosphatase family. Further characterization of the enzymatic properties of synaptojanin now shows that it hydrolyzes only the 5-phosphate from inositol 1,4,5-trisphosphate (I(1,4,5)P3) and that it does not catalyze the dephosphorylation of either I(1,3,4)P3 or inositol 1,4-bisphosphate. However, synaptojanin hydrolyzes both the 4- and 5-phosphates of PI(4,5)P2 and the 4-phosphate of phosphatidylinositol 4-phosphate, converting both compounds to phosphatidylinositol. Magnesium is required for the hydrolysis of I(1,4,5)P3, but not for that of phosphoinositides, by synaptojanin. The inhibition of PLD by synaptojanin is attributable to its ability to hydrolyze PI(4,5)P2. Synaptojanin did not inhibit PLD in the absence of PI(4,5)P2, and the extent of PLD inhibition was related to the extent of PI(4,5)P2hydrolysis in substrate vesicles. It has been proposed that the biosynthesis of PI(4,5)P2 and the activation of PLD by ADP-ribosylation factor constitute a positive loop to increase rapidly the concentrations of PI(4,5)P2 and phosphatidic acid (PA) during membrane vesiculation. The PA thus produced, probably together with PI(4,5)P2, facilitates vesicle coat assembly. The hydrolysis of PI(4,5)P2, and consequent inhibition of PLD, by synaptojanin might therefore constitute a mechanism to halt the positive loop connecting PI(4,5)P2 and PA during the endocytotic cycle of synaptic vesicles and serve as a signal for uncoating. A 150-kDa protein that inhibits phospholipase D (PLD) activity stimulated by ADP-ribosylation factor and phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) was previously purified from rat brain. The sequences of peptides derived from the purified PLD inhibitor now identify it as synaptojanin, a nerve terminal protein that has been implicated in the endocytosis of fused synaptic vesicles and shown to be a member of the inositol polyphosphate 5-phosphatase family. Further characterization of the enzymatic properties of synaptojanin now shows that it hydrolyzes only the 5-phosphate from inositol 1,4,5-trisphosphate (I(1,4,5)P3) and that it does not catalyze the dephosphorylation of either I(1,3,4)P3 or inositol 1,4-bisphosphate. However, synaptojanin hydrolyzes both the 4- and 5-phosphates of PI(4,5)P2 and the 4-phosphate of phosphatidylinositol 4-phosphate, converting both compounds to phosphatidylinositol. Magnesium is required for the hydrolysis of I(1,4,5)P3, but not for that of phosphoinositides, by synaptojanin. The inhibition of PLD by synaptojanin is attributable to its ability to hydrolyze PI(4,5)P2. Synaptojanin did not inhibit PLD in the absence of PI(4,5)P2, and the extent of PLD inhibition was related to the extent of PI(4,5)P2hydrolysis in substrate vesicles. It has been proposed that the biosynthesis of PI(4,5)P2 and the activation of PLD by ADP-ribosylation factor constitute a positive loop to increase rapidly the concentrations of PI(4,5)P2 and phosphatidic acid (PA) during membrane vesiculation. The PA thus produced, probably together with PI(4,5)P2, facilitates vesicle coat assembly. The hydrolysis of PI(4,5)P2, and consequent inhibition of PLD, by synaptojanin might therefore constitute a mechanism to halt the positive loop connecting PI(4,5)P2 and PA during the endocytotic cycle of synaptic vesicles and serve as a signal for uncoating. The hydrolysis of phosphatidylcholine (PC) 1The abbreviations used are: PC, phosphatidylcholine; PLD, phospholipase D; hPLD1, human PLD1; PLC, phospholipase C; (pam)2PC, dipalmitoyl PC; PE, phosphatidylethanolamine; PA, phosphatidic acid; PEtOH, phosphatidylethanol; PI(4,5)P2, phosphatidylinositol 4,5-bisphosphate; PI(4)P, phosphatidylinositol 4-phosphate; PI, phosphatidylinositol; PIP, phosphatidylinositol phosphate; I(1,3,4,5)P4, inositol 1,3,4,5-tetrakisphosphate; I(1,4,5)P3, inositol 1,4,5-trisphosphate; I(1,4)P2, inositol 1,4-bisphosphate; ARF, ADP-ribosylation factor; GTPγS, guanosine 5′-O-(thiotriphosphate); IP 5-Pase, inositol polyphosphate 5-phosphatase; SH3, Src homology 3. to phosphatidic acid (PA) and choline catalyzed by phospholipase D (PLD) appears to be a crucial step for transmembrane signaling by many cell surface receptors as well as for membrane trafficking (1Exton J.H. Biochim. Biophys. Acta. 1994; 1212: 26-42Crossref PubMed Scopus (920) Google Scholar, 2Ktistakis N.T. Brown H.A. Waters M.G. Sternweis P.C. Roth M.G. J. Cell Biol. 1996; 134: 295-306Crossref PubMed Scopus (329) Google Scholar). PA functions as an intracellular messenger and can be further hydrolyzed by a PA-specific phosphatase to form diacylglycerol, an activator of protein kinase C. Mammalian PLD appears to exist in multiple isoforms (3Hammond S.M. Altshuller Y.M. Sung T.-C. Rudge S.A. Rose K. Engebrecht J. Morris A.J. Frohman M.A. J. Biol. Chem. 1995; 270: 29640-29643Abstract Full Text Full Text PDF PubMed Scopus (598) Google Scholar), the activation of some of which requires a member of the family of small GTP-binding proteins, ADP-ribosylation factor (ARF) (4Brown H.A. Gutowski S. Moomaw C.R. Slaughter Y.C. Sternweis P.C. Cell. 1993; 75: 1137-1144Abstract Full Text PDF PubMed Scopus (821) Google Scholar, 5Cockcroft S. Thomas G.M.H. Fensome A. Geny B. Cunningham E. Gout I. Hiles I. Totty N.F. Truong O. Hsuan J.J. Science. 1994; 263: 523-526Crossref PubMed Scopus (585) Google Scholar). The activity of such PLD isoforms is further enhanced by the presence of PI(4,5)P2, but not by the presence of PI or PI(4)P in the substrate vesicles (4Brown H.A. Gutowski S. Moomaw C.R. Slaughter Y.C. Sternweis P.C. Cell. 1993; 75: 1137-1144Abstract Full Text PDF PubMed Scopus (821) Google Scholar, 6Liscovitch M. Chalifa V. Pertile P. Chen C.-S. Cantley L.C. J. Biol. Chem. 1994; 269: 21403-21406Abstract Full Text PDF PubMed Google Scholar). Human PLD1 (hPLD1), one of the PLD isoforms activated by ARF and PI(4,5)P2, has been cloned (3Hammond S.M. Altshuller Y.M. Sung T.-C. Rudge S.A. Rose K. Engebrecht J. Morris A.J. Frohman M.A. J. Biol. Chem. 1995; 270: 29640-29643Abstract Full Text Full Text PDF PubMed Scopus (598) Google Scholar). We recently identified multiple proteins that inhibit the activity of ARF- and PI(4,5)P2-stimulated PLD (7Han J.-S. Chung J.-K. Kang H.-S. Donaldson J. Bae Y.S. Rhee S.G. J. Biol. Chem. 1996; 271: 11163-11169Abstract Full Text Full Text PDF PubMed Scopus (22) Google Scholar). One of these inhibitors was purified to homogeneity to yield a 150-kDa protein that was tentatively named inhibitor IA. Sequences of two tryptic peptides derived from IA protein were determined (7Han J.-S. Chung J.-K. Kang H.-S. Donaldson J. Bae Y.S. Rhee S.G. J. Biol. Chem. 1996; 271: 11163-11169Abstract Full Text Full Text PDF PubMed Scopus (22) Google Scholar), but at the time they did not match any protein sequences in the data bases. However, a subsequent search revealed that the two sequences, EANAPAFD and GSVPLFWE, match exactly those of residues 276–283 and residues 251–258, respectively, of synaptojanin, a protein that is enriched in nerve terminals and was recently cloned (8McPherson P.S. Garcia E.P. Slepnev V.I. David C. Zhang X. Grabs D. Sossin W.S. Bauerfeind R. Nemoto Y. De Camilli P. Nature. 1996; 379: 353-357Crossref PubMed Scopus (492) Google Scholar). In the accompanying paper (9Lee C. Kang H.-S. Chung J.-K. Sekiya F. Kim J.-R. Han J.-S. Kim S.R. Bae Y.S. Morris A.J. Rhee S.G. J. Biol. Chem. 1997; 272: 15986-15992Abstract Full Text Full Text PDF PubMed Scopus (54) Google Scholar), we purified another inhibitor termed IB and identified it as clathrin assembly protein 3 (AP-3). The central region of synaptojanin is highly homologous to a family of inositol polyphosphate 5-phosphatases (IP 5-Pases) that catalyzes the dephosphorylation of inositol polyphosphates or phosphoinositides at the 5′-position of the inositol ring (8McPherson P.S. Garcia E.P. Slepnev V.I. David C. Zhang X. Grabs D. Sossin W.S. Bauerfeind R. Nemoto Y. De Camilli P. Nature. 1996; 379: 353-357Crossref PubMed Scopus (492) Google Scholar). Indeed, synaptojanin was shown to possess IP 5-Pase activity (8McPherson P.S. Garcia E.P. Slepnev V.I. David C. Zhang X. Grabs D. Sossin W.S. Bauerfeind R. Nemoto Y. De Camilli P. Nature. 1996; 379: 353-357Crossref PubMed Scopus (492) Google Scholar). Here, we confirm that inhibitor IA is indeed synaptojanin, characterize its catalytic properties, and show that it inhibits PLD by hydrolyzing PI(4,5)P2. Rat brains were obtained from Pel-Freez Biologicals (Rogers, AR); bovine brain PC and phosphatidylethanolamine (PE) were from Avanti Polar Lipids (Alabaster, AL); GTPγS and PI(4,5)P2 were from Boehringer Mannheim; [choline-methyl-3H]dipalmitoyl PC [(pam)2PC] (50 Ci/mmol), [2-palmitoyl-9,10-3H](pam)2PC (89 Ci/mmol), [inositol-2-3H]PI(4,5)P2(7 Ci/mmol), and [2-3H]inositol 1,4,5-trisphosphate [I(1,4,5)P3] (21 Ci/mmol) were from DuPont NEN; andn-octyl-β-d-glucopyranoside was from Calbiochem. Partially purified PLD as well as homogeneous preparations of the 150-kDa PLD inhibitor IA (synaptojanin) and ARF were obtained from rat brain as described (7Han J.-S. Chung J.-K. Kang H.-S. Donaldson J. Bae Y.S. Rhee S.G. J. Biol. Chem. 1996; 271: 11163-11169Abstract Full Text Full Text PDF PubMed Scopus (22) Google Scholar). PLC-β1, PLC-γ1, and PLC-δ1 were purified as described (10Hwang S.C. Jhon D.-Y. Bae Y.S. Kim J.H. Rhee S.G. J. Biol. Chem. 1996; 271: 18342-18349Abstract Full Text Full Text PDF PubMed Scopus (159) Google Scholar). hPLD1 was partially purified from Sf9 insect cells that had been infected with a recombinant baculovirus harboring the hPLD1 cDNA (3Hammond S.M. Altshuller Y.M. Sung T.-C. Rudge S.A. Rose K. Engebrecht J. Morris A.J. Frohman M.A. J. Biol. Chem. 1995; 270: 29640-29643Abstract Full Text Full Text PDF PubMed Scopus (598) Google Scholar), using an identical procedure. The cells were suspended in ice-cold lysis buffer (20 mmTris-HCl (pH 7.5), 1 mm EGTA, 1 mmMgCl2, 1 mm dithiothreitol, 0.1 mm4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride), and disrupted by sonication. The lysate was centrifuged at 1000 × gfor 5 min, and the resulting supernatant was centrifuged at 50,000 × g for 30 min. The pellet from the second centrifugation step was resuspended in lysis buffer containing 0.7%n-octyl-β-d-glucopyranoside and stirred for 1 h. After centrifugation at 12,000 × g for 15 min, solubilized proteins (∼5 mg of protein in 5 ml) were applied onto a TSK-gel heparin-5PW column (7.5 × 75 mm) that had been equilibrated with 20 mm Hepes-NaOH (pH 7.0), 1 mm EGTA, 1 mm dithiothreitol, and 0.7%n-octyl-β-d-glucopyranoside. Proteins were eluted from the column with a linear gradient of 0–1.0 mNaCl in 60 ml of equilibration buffer. Fractions (1 ml) were collected at a flow rate of 1 ml/min and assayed for PLD activity as described below. Peak fractions (fractions 54–60) were pooled to yield 190 μg of protein. The proteins were then divided into aliquots (25 μl) and stored at −70 °C. After thawing, the enzyme was used within several hours. ARF-dependent PLD activity was assayed, essentially as described (7Han J.-S. Chung J.-K. Kang H.-S. Donaldson J. Bae Y.S. Rhee S.G. J. Biol. Chem. 1996; 271: 11163-11169Abstract Full Text Full Text PDF PubMed Scopus (22) Google Scholar), by measuring the generation of either 3H-labeled PA and phosphatidylethanol (PEtOH) from [2-palmitoyl-9,10-3H](pam)2PC in the presence of ethanol or 3H-labeled choline from [choline-methyl- 3H](pam)2PC. Briefly, 25 μl of lipid vesicles containing PE, PI(4,5)P2, and PC in molar ratio of 16:1.4:1 with either [2-palmitoyl-9,10-3H](pam)2PC (total ∼106 cpm/assay) or [choline-methyl- 3H] (pam)2PC (total ∼200,000 cpm/assay) were added to 125 μl of a mixture containing PLD source, 100 nm ARF, 5 μmGTPγS, 50 mm Hepes-NaOH (pH 7.5), 3 mm EGTA, 80 mm KCl, 2.5 mm MgCl2, and 2 mm CaCl2. The final concentration of PC was 3.4 μm, and the free Ca2+ concentration was calculated to be 300 nm. The assay mixture for the measurement of PA and PEtOH also contained 0.67% (v/v) ethanol. The reaction mixture was incubated at 37 °C for 1 h for the measurement of PA and PEtOH and for 30 min for the measurement of choline. The reaction was terminated by the addition of 1 ml of stop solution containing chloroform, methanol, and concentrated HCl (50:50:0.3, v/v) and 0.35 ml of 1 m HCl containing 5 mm EGTA. After separation of the organic and aqueous phases by centrifugation, the former was analyzed by thin-layer chromatography (TLC) for the measurement of [3H]PA and [3H]PEtOH as described (11Pai J.-K Siegel M.I. Egan R.W. Billah M.M. J. Biol. Chem. 1988; 263: 12472-12477Abstract Full Text PDF PubMed Google Scholar); alternatively, [3H]choline in the aqueous phase was measured directly, as described (7Han J.-S. Chung J.-K. Kang H.-S. Donaldson J. Bae Y.S. Rhee S.G. J. Biol. Chem. 1996; 271: 11163-11169Abstract Full Text Full Text PDF PubMed Scopus (22) Google Scholar). Mixed phospholipid vesicles containing PE, PI(4,5)P2, and PC in a molar ratio of 16:1.4:1 with [inositol-2-3H]PI(4,5)P2 to yield ∼26,000 cpm/assay were prepared. Assays were initiated by adding 170 ng of PLC to a 100-μl reaction mixture containing the phospholipid vesicles, various concentrations of synaptojanin, 50 mmHepes-NaOH (pH 7.0), 10 mm NaCl, 120 mm KCl, 2 mm EGTA, 2.0 mm CaCl2, and 25 ng of bovine serum albumin. The final concentrations of PI(4,5)P2and free Ca2+ were 4.8 μm and 0.1 mm, respectively. After 10 min at 30 °C, the reaction was terminated and the amount of [3H]I(1,4,5)P3 was quantitated as described (10Hwang S.C. Jhon D.-Y. Bae Y.S. Kim J.H. Rhee S.G. J. Biol. Chem. 1996; 271: 18342-18349Abstract Full Text Full Text PDF PubMed Scopus (159) Google Scholar). We purified three additional tryptic peptides of inhibitor IA; their sequences (QQNWDSLIAGDQLINQK, SAEDLDLLNAS, and EVIAVQGPPD) matched exactly those of synaptojanin residues 748–764, 820–830, and 884–893, respectively. Furthermore, rabbit antiserum prepared against inhibitor IA recognized a 150-kDa protein in rat brain homogenate but not in the homogenates of other rat tissues including liver, kidney, lung, heart, and spleen (data not shown). This tissue distribution is consistent with the nerve terminal-specific expression of synaptojanin (12McPherson P.S. Takei K. Schmid S.L. De Camilli P. J. Biol. Chem. 1994; 269: 30132-30139Abstract Full Text PDF PubMed Google Scholar). These results confirm that inhibitor IA is synaptojanin. Given that synaptojanin is an IP 5-Pase, we investigated the possibility that synaptojanin inhibits PLD by hydrolyzing the activator PI(4,5)P2. First, the inhibitory activity of synaptojanin was evaluated in the absence of PI(4,5)P2. The ARF-dependent activity of hPLD1 in the absence of PI(4,5)P2 is ∼5% of that in its presence, so the amount of hPLD1 used to measure activity in the absence of PI(4,5)P2 was 20 times that used in the presence of the activator. Because this increased amount of partially purified hPLD1 might introduce enzymes that cause nonspecific hydrolysis of PC, we measured the production of PEtOH, as well as that of PA, from [2-palmitoyl-9,10-3H](pam)2PC in the presence of ethanol. PLD attacks PC to form a transient phosphatidyl-PLD intermediate. With water as an acceptor, PA is the product; however, in the presence of ethanol, the phosphatidyl moiety is also transferred to the alcohol, generating PEtOH, in a reaction specific to PLD (11Pai J.-K Siegel M.I. Egan R.W. Billah M.M. J. Biol. Chem. 1988; 263: 12472-12477Abstract Full Text PDF PubMed Google Scholar). Whereas synaptojanin at 8 nmcompletely inhibited the formation of both PA and PEtOH in the presence of PI(4,5)P2, it had no effect on the formation of either product in the absence of PI(4,5)P2 (Fig.1).Figure 1Effects of synaptojanin on ARF-dependent hPLD1 activity in the absence or presence of PI(4,5)P2. hPLD1 (11 ng for lanes 2 and3, and 216 ng for lanes 5 and 6) was incubated with phospholipid substrate vesicles in a reaction mixture containing 0.67% (v/v) ethanol in the absence (lanes 2 and5) or presence (lanes 3 and 6) of 8 nm synaptojanin. The substrate vesicles comprised either PE, PI(4,5)P2, and [2-palmitoyl-9,10-3H](pam)2PC in a molar ratio of 16:1.4:1 (lanes 1–3) or PE and [2-palmitoyl-9,10-3H](pam)2PC in a molar ratio of 16:1 (lanes 4–6). The final concentration and specific radioactivity of PC were identical in the two substrate systems. After incubation for 1 h at 37 °C, the lipid products were analyzed by TLC and visualized by autoradiography. The positions of PC, PA, and PEtOH are indicated. Lanes 1 and 4represent analysis of the reaction mixture before the addition of hPLD1.View Large Image Figure ViewerDownload Hi-res image Download (PPT) We next incubated substrate vesicles containing PE, PI(4,5)P2, and [choline-methyl- 3H](pam)2PC in a molar ratio of 16:1.4:1 with synaptojanin for various times before the addition of hPLD1. The activity of hPLD1 decreased as the time of preincubation of vesicles with synaptojanin increased (Fig.2). The extent of PI(4,5)P2 hydrolysis during the preincubation with synaptojanin was measured with substrate vesicles with a lipid composition identical to that for the PLD inhibition assay with the exception that the 3H-labeled lipid was PI(4,5)P2 instead of PC. Under this assay condition, only ∼20% of total PI(4,5)P2 appeared to be available for hydrolysis by synaptojanin (Figs. 2 and3), probably because the lipid substrate consisted predominantly of multilamellar vesicles with only 20% of their PI(4,5)P2 exposed to the enzyme. Nevertheless, the extent of PI(4,5)P2 hydrolysis correlated qualitatively with the extent of PLD inhibition (Fig. 2). The products of PI(4,5)P2 hydrolysis by synaptojanin were analyzed with the use of substrate vesicles containing PE, PI(4,5)P2, and PC (Fig. 3). The major product was PI rather than PIP; the amount of PIP produced varied from negligible (Fig.3 A) to ∼25% of that of PI (see Fig. 5). However, with a micellar substrate containing 0.1% Triton X-100 and PI(4,5)P2, synaptojanin generated PIP and PI in a 3:1 ratio (data not shown). The hydrolysis of PI(4)P was demonstrated directly with vesicles containing PE, PI(4)P, and PC in a molar ratio of 16:1.4:1; the rate of PI(4)P hydrolysis was ∼1.5 times that of PI(4,5)P2 hydrolysis measured with vesicles of identical lipid composition with the exception that PI(4)P was replaced by PI(4,5)P2 (data not shown). These results suggest that the relative rates of hydrolysis of PI(4,5)P2 and PI(4)P by synaptojanin depend on the physical nature of the substrate. Because PI(4)P and PI(5)P cannot be distinguished by TLC, we do not know whether synaptojanin dephosphorylates PI(4,5)P2sequentially, the 5-phosphate followed by the 4-phosphate (orvice versa), or randomly. The hydrolysis of PI(4,5)P2 by synaptojanin was dependent on the concentration of the latter (Fig. 3 B). We tested the phosphatase activity of synaptojanin with I(1,4,5)P3, I(1,3,4)P3, and I(1,4)P2. As previously shown (8McPherson P.S. Garcia E.P. Slepnev V.I. David C. Zhang X. Grabs D. Sossin W.S. Bauerfeind R. Nemoto Y. De Camilli P. Nature. 1996; 379: 353-357Crossref PubMed Scopus (492) Google Scholar), I(1,4,5)P3was converted to IP2 in a synaptojanin concentration-dependent manner, and no further dephosphorylation to IP was observed (Fig.4 A). Hydrolysis of I(1,3,4)P3(Fig. 4 B) or I(1,4)P2 (Fig. 4 C) was not apparent, even in the presence of high concentrations of synaptojanin. Thus, unlike the situation with phosphoinositides, the hydrolysis of inositol polyphosphates by synaptojanin appears specific to the 5-phosphate. Furthermore, whereas the hydrolysis of PI(4,5)P2 by synaptojanin did not require Mg2+(the rate was slightly faster in the absence of Mg2+), the synaptojanin-catalyzed hydrolysis of I(1,4,5)P3 was absolutely dependent on the presence of Mg2+ (Fig.5). We previously showed that inhibitor IA (synaptojanin) did not inhibit the PI(4,5)P2-hydrolyzing activity of phospholipase C-γ1 (PLC-γ1) when measured with substrate vesicles containing PE, PI(4,5)P2, and PC in a molar ratio of 16:1.4:1 (7Han J.-S. Chung J.-K. Kang H.-S. Donaldson J. Bae Y.S. Rhee S.G. J. Biol. Chem. 1996; 271: 11163-11169Abstract Full Text Full Text PDF PubMed Scopus (22) Google Scholar). Inhibition was not apparent probably because PLC activity was assayed by measuring the release of water-soluble 3H-labeled inositol phosphates from [inositol- 3H]PI(4,5)P2 and because PI and PIP derived from dephosphorylation of PI(4,5)P2 by synaptojanin are also substrates for PLC-γ1. PLC-β1, PLC-γ1, and PLC-δ1 all hydrolyze PI, PIP, and PI(4,5)P2, but the selectivity for PI(4,5)P2 over PI decreases in the rank order PLC-β1 > PLC-δ1 > PLC-γ1 (13Ryu S.H. Suh P.-G. Cho K.S. Lee K.-Y. Rhee S.G. Proc. Natl. Acad. Sci. U. S. A. 1987; 84: 6649-6653Crossref PubMed Scopus (160) Google Scholar). We therefore studied the effect of synaptojanin on the [inositol- 3H]PI(4,5)P2-hydrolyzing activity of the three PLC isozymes (Fig. 6). Whereas the activity of PLC-γ1 was not affected, the activities of PLC-β1 and PLC-δ1 were inhibited by synaptojanin in a concentration-dependent manner. The rank order of the extent of inhibition, PLC-β1 > PLC-δ1 > PLC-γ1, is consistent with the selectivity of the PLC isozymes for PI(4,5)P2 over PI. IP 5-Pases vary markedly in both molecular size and amino acid sequence. However, they contain two short motifs (of six to nine amino acids) that are separated by fairly constant numbers of amino acids (14Jefferson A.B. Majerus P.W. J. Biol. Chem. 1995; 270: 9370-9377Abstract Full Text Full Text PDF PubMed Scopus (118) Google Scholar, 15Majerus P.W. Genes Dev. 1996; 10: 1051-1053Crossref PubMed Scopus (50) Google Scholar, 16Kavanaugh W.M. Pot D.A. Chin S.M. Deuter-Reinhard M. Jefferson A.B. Norris F.A. Masiarz F.R. Cousens L.S. Majerus P.W. Williams L.T. Curr. Biol. 1996; 4: 438-445Abstract Full Text Full Text PDF Scopus (207) Google Scholar). The enzymes have been classified according to their substrate specificity (15Majerus P.W. Genes Dev. 1996; 10: 1051-1053Crossref PubMed Scopus (50) Google Scholar): Group 1 enzymes hydrolyze I(1,4,5)P3 and I(1,3,4,5)P4 but not lipid substrates such as PI(4,5)P2 and PI(3,4,5)P3, group 2 enzymes hydrolyze the two inositol phosphate substrates [I(1,4,5)P3 and I(1,3,4,5)P4] as well as the two lipid substrates [PI(4,5)P2 and PI(3,4,5)P3], and group 3 enzymes hydrolyze only substrates containing a 3-phosphate [PI(3,4,5)P3 and I(1,3,4,5)P4]. The central region of synaptojanin contains the two IP 5-Pase-specific motifs and was previously shown, in the presence of Mg2+, to hydrolyze I(1,4,5)P3 and I(1,3,4,5)P4, but not I(1,3,4)P3, and was reported to convert PI(4,5)P2 to an unspecified PIP (8McPherson P.S. Garcia E.P. Slepnev V.I. David C. Zhang X. Grabs D. Sossin W.S. Bauerfeind R. Nemoto Y. De Camilli P. Nature. 1996; 379: 353-357Crossref PubMed Scopus (492) Google Scholar). Synaptojanin was, therefore, considered a group 2 IP 5-Pase (15Majerus P.W. Genes Dev. 1996; 10: 1051-1053Crossref PubMed Scopus (50) Google Scholar). The 75-kDa human platelet IP 5-Pase, a group 2 member, also requires Mg2+for activity (17Matzaris M. Jackson S.P. Laxminarayan K.M. Speed C.J. Mitchell C.A. J. Biol. Chem. 1994; 269: 3397-3402Abstract Full Text PDF PubMed Google Scholar). We have now further characterized the catalytic properties of synaptojanin with a homogeneous preparation. The synaptojanin used in the previous study of McPherson et al. (8McPherson P.S. Garcia E.P. Slepnev V.I. David C. Zhang X. Grabs D. Sossin W.S. Bauerfeind R. Nemoto Y. De Camilli P. Nature. 1996; 379: 353-357Crossref PubMed Scopus (492) Google Scholar) was either immunoprecipitated with antibodies to synaptojanin or had been exposed to a denaturing condition during purification. Our data suggest that synaptojanin specifically hydrolyzes the 5-phosphate in inositol polyphosphates. However, it dephosphorylates both the 5- and 4-positions, showing a preference for the 4-phosphate over the 5-phosphate under certain conditions, of lipid substrates. Furthermore, Mg2+ was not required for the activity toward lipid substrates. Synaptojanin thus resembles the 90-kDa polyphosphoinositide phosphatase purified from rat brain, which hydrolyzes phosphate from the 4- and 5-positions of PI(4,5)P2 to yield PI in the absence of Mg2+ (18Hope H.M.R. Pike L.J. J. Biol. Chem. 1994; 269: 23648-23654Abstract Full Text PDF PubMed Google Scholar). However, the 90-kDa enzyme is specific for phosphoinositides and does not act on I(1,4,5)P3 (18Hope H.M.R. Pike L.J. J. Biol. Chem. 1994; 269: 23648-23654Abstract Full Text PDF PubMed Google Scholar). The characteristics of the NH2- and COOH-terminal regions of synaptojanin suggest a possible role in membrane trafficking. The NH2-terminal region is similar to the cytosolic domain of yeast SacI protein (8McPherson P.S. Garcia E.P. Slepnev V.I. David C. Zhang X. Grabs D. Sossin W.S. Bauerfeind R. Nemoto Y. De Camilli P. Nature. 1996; 379: 353-357Crossref PubMed Scopus (492) Google Scholar). The sac1 gene was identified as a suppressor of the sec14 mutant, which is defective in post-Golgi membrane trafficking (19Cleves A.E. Novick P.J. Bankaitis V.A. J. Cell Biol. 1989; 109: 2939-2950Crossref PubMed Scopus (191) Google Scholar); Sec14 protein is a PI transfer protein. The proline-rich COOH terminus of synaptojanin interacts with the Src homology 3 (SH3) domains of amphiphysin (8McPherson P.S. Garcia E.P. Slepnev V.I. David C. Zhang X. Grabs D. Sossin W.S. Bauerfeind R. Nemoto Y. De Camilli P. Nature. 1996; 379: 353-357Crossref PubMed Scopus (492) Google Scholar) and Grb-2 (12McPherson P.S. Takei K. Schmid S.L. De Camilli P. J. Biol. Chem. 1994; 269: 30132-30139Abstract Full Text PDF PubMed Google Scholar), which also bind to the proline-rich domain of dynamin. Dynamin is a GTPase that colocalizes with synaptojanin in nerve terminals and functions in the closure of coated vesicles budding from the plasmalemma, including nerve terminal clathrin-coated vesicles that participate in the recycling of synaptic vesicle membranes after exocytosis (12McPherson P.S. Takei K. Schmid S.L. De Camilli P. J. Biol. Chem. 1994; 269: 30132-30139Abstract Full Text PDF PubMed Google Scholar, 20De Camilli P. Emr S.D. McPherson P.S. Novick P. Science. 1996; 271: 1533-1539Crossref PubMed Scopus (661) Google Scholar). Amphiphysin also interacts with the clathrin adapter protein AP-2 through a region distinct from its SH3 domain and may therefore help concentrate dynamin and synaptojanin at clathrin-coated pits (20De Camilli P. Emr S.D. McPherson P.S. Novick P. Science. 1996; 271: 1533-1539Crossref PubMed Scopus (661) Google Scholar, 21David C. McPherson P.S. Mundigl O. De Camilli P. Proc. Natl. Acad. Sci. U. S. A. 1996; 93: 331-335Crossref PubMed Scopus (350) Google Scholar). Amphiphysin contains regions that are similar to the yeast proteins Rvs161p and Rvs167p, mutations in which result in defects in endocytosis (22David C. Solimena M. De Camilli P. FEBS Lett. 1994; 351: 73-79Crossref PubMed Scopus (130) Google Scholar, 23Sivadon P. Bauer F. Aigle M. Crouzet M.I. Mol. Gen. Genet. 1995; 246: 485-495Crossref PubMed Scopus (113) Google Scholar, 24Munn A.L. Stevenson B.J. Geli M.I. Riezman H. Mol. Biol. Cell. 1995; 6: 1721-1742Crossref PubMed Scopus (280) Google Scholar). On the basis of these observations, synaptojanin was suggested to participate with dynamin and amphiphysin in the endocytotic pathway of synaptic vesicles (12McPherson P.S. Takei K. Schmid S.L. De Camilli P. J. Biol. Chem. 1994; 269: 30132-30139Abstract Full Text PDF PubMed Google Scholar,20De Camilli P. Emr S.D. McPherson P.S. Novick P. Science. 1996; 271: 1533-1539Crossref PubMed Scopus (661) Google Scholar, 21David C. McPherson P.S. Mundigl O. De Camilli P. Proc. Natl. Acad. Sci. U. S. A. 1996; 93: 331-335Crossref PubMed Scopus (350) Google Scholar). A growing body of evidence indicates that phosphoinositide metabolism is critical for the regulation of vesicular traffic (20De Camilli P. Emr S.D. McPherson P.S. Novick P. Science. 1996; 271: 1533-1539Crossref PubMed Scopus (661) Google Scholar). Studies on Ca2+-dependent neurotransmitter release from permeabilized PC12 cells indicate that PI transfer protein and PIP 5-kinase are cytosolic factors required for exocytosis (25Hay J.C. Fisette P.L. Jenkins G.H. Fukami K. Takenawa T. Anderson R.A. Martin T.F.J. Nature. 1995; 374: 173-177Crossref PubMed Scopus (451) Google Scholar), probably because the generation of PI(4,5)P2 is a critical event in priming. It is thought that PI transfer protein presents PI to PI 4-kinase associated with secretory vesicles; PI is thus phosphorylated to PI(4)P, which is further converted to PI(4,5)P2 by PIP 5-kinase. PI(4,5)P2 binds AP-2 and dynamin, both of which function in clathrin-mediated endocytosis. Therefore, the generation of PI(4,5)P2 appears to be important for not only exocytosis but also subsequent budding of the discharged vesicles. Studies on the formation of coatomer-coated Golgi vesicles also suggest a role for PI(4,5)P2 in bud formation. Cytosolic ARF has been proposed to exchange bound GDP for GTP at the Golgi surface; the resulting Golgi-bound ARF-GTP then recruits coatomer from the cytosol to assemble the bud (26Rothman J.E. Nature. 1994; 372: 55-63Crossref PubMed Scopus (2007) Google Scholar). PI(4,5)P2 stimulates the ARF GTP-GDP exchange reaction (27Terui T. Kahn R.A. Randazzo P.A. J. Biol. Chem. 1994; 269: 28130-28135Abstract Full Text PDF PubMed Google Scholar), and might thereby contribute to coat assembly. PI(4,5)P2, together with the GTP-bound ARF, also activates PLD, with the resulting generation of PA (6Liscovitch M. Chalifa V. Pertile P. Chen C.-S. Cantley L.C. J. Biol. Chem. 1994; 269: 21403-21406Abstract Full Text PDF PubMed Google Scholar). PA stimulates the activity of PI(4)P 5-kinase (28Jenkins G.H. Fisette P.L. Anderson R.A. J. Biol. Chem. 1994; 269: 11547-11554Abstract Full Text PDF PubMed Google Scholar), resulting in increased synthesis of PI(4,5)P2, which, in turn, would cause further stimulation of ARF and PLD activity, leading to more production of PA and PI(4,5)P2. This positive feedback loop would be expected to cause a rapid increase in PA and PI(4,5)P2 and result in a substantial change in the microdomain architecture of the lipid bilayer that would facilitate coat assembly (29Liscovitch M. Cantley L.C. Cell. 1995; 81: 659-662Abstract Full Text PDF PubMed Scopus (248) Google Scholar). The hydrolysis of ARF-bound GTP stimulated by an ARF-specific GTPase-activating protein has been proposed as a signal for terminating the positive feedback loop (29Liscovitch M. Cantley L.C. Cell. 1995; 81: 659-662Abstract Full Text PDF PubMed Scopus (248) Google Scholar) and serving as a switch for uncoating (26Rothman J.E. Nature. 1994; 372: 55-63Crossref PubMed Scopus (2007) Google Scholar). Consistent with this model, loading ARF with GTPγS was shown to prevent uncoating and induce an accumulation of coated vesicles (26Rothman J.E. Nature. 1994; 372: 55-63Crossref PubMed Scopus (2007) Google Scholar). Recent studies by Ktistakis et al. (2Ktistakis N.T. Brown H.A. Waters M.G. Sternweis P.C. Roth M.G. J. Cell Biol. 1996; 134: 295-306Crossref PubMed Scopus (329) Google Scholar) indicate that the dual actions of ARF, activation of PLD and induction of coatomer binding, are related events. ARF-dependent PLD is abundant in Golgi membranes (30Ktistakis N.T. Brown H.A. Sternweis P.C. Roth M.G. Proc. Natl. Acad. Sci. U. S. A. 1995; 92: 4952-4956Crossref PubMed Scopus (181) Google Scholar). When Golgi membranes were prepared from cell lines with high constitutive PLD activity, cytosolic ARF was not necessary for initiating coat assembly. Furthermore, the generation of PA in Golgi membranes by an exogenous bacterial PLD was shown to induce coatomer binding. Purified coatomer also bound selectively to artificial lipid vesicles that contained PA and PI(4,5)P2. These observations led Ktistakis et al. to propose that the main role of activated ARF is to activate PLD, and that both the PA produced by the activated PLD and PI(4,5)P2, not ARF, are responsible for stable binding of coatomer (2Ktistakis N.T. Brown H.A. Waters M.G. Sternweis P.C. Roth M.G. J. Cell Biol. 1996; 134: 295-306Crossref PubMed Scopus (329) Google Scholar). The observations of Ktistakis et al. (2Ktistakis N.T. Brown H.A. Waters M.G. Sternweis P.C. Roth M.G. J. Cell Biol. 1996; 134: 295-306Crossref PubMed Scopus (329) Google Scholar) also raise a question with regard to the proposed role of the hydrolysis of ARF-bound GTP as the signal for uncoating and the halt of the positive loop between PA and PI(4,5)P2 generation. One can hypothesize that hydrolysis of PI(4,5)P2 by a specific phosphatase might instead constitute such a signal; the resulting decrease in PI(4,5)P2 concentration would result in the deactivation of PLD as well as in the termination of the PI(4,5)P2-dependent GTP-GDP exchange on ARF. In support of this hypothesis, an IP 5-Pase, termed OCRL, has been specifically localized to the Golgi complex (31Olivos-Glander I.M. Pasi A.J. Nussbaum R.L. Am. J. Hum. Genet. 1993; 57: 817-823Google Scholar). Mutations in theOCRL gene are responsible for the oculocerebrorenal syndrome of Lowe (OCRL), which is characterized by mental retardation, cataracts, and defects in renal tubular absorption (32Attree O. Olivos I.M. Okabe I. Bailey L.C. Nelson D.L. Lewis R.A. McInnes R.R. Nussbaum R.L. Nature. 1992; 358: 239-242Crossref PubMed Scopus (407) Google Scholar). We have recently shown that OCRL protein inhibits ARF-activated PLD. 2F. Sekiya, C. Lee, and S. G. Rhee, unpublished observation. PLD activity has not been detected in association with synaptic vesicles. However, by analogy with Golgi vesicular traffic, a similar positive interaction between PI(4,5)P2 formation and PLD activation may play a regulatory role in clathrin coating. Furthermore, the hydrolysis of PI(4,5)P2 by synaptojanin may serve to interrupt the positive loop and to act as the signal for uncoating. In such a model, it would be important that synaptojanin acts on PI(4,5)P2 after coating. Such timing might be achieved through the SH3-dependent interaction with amphiphysin or phosphorylation of synaptojanin. Synaptojanin, like dynamin, is a phosphoprotein that undergoes dephosphorylation in response to nerve terminal depolarization (12McPherson P.S. Takei K. Schmid S.L. De Camilli P. J. Biol. Chem. 1994; 269: 30132-30139Abstract Full Text PDF PubMed Google Scholar). We thank Rodney Levine and Michael Nauman for peptide sequencing." @default.
• W1984152194 created "2016-06-24" @default.
• W1984152194 creator A5000115883 @default.
• W1984152194 creator A5006178861 @default.
• W1984152194 creator A5012014295 @default.
• W1984152194 creator A5012840606 @default.
• W1984152194 creator A5020834497 @default.
• W1984152194 creator A5022011748 @default.
• W1984152194 creator A5037597705 @default.
• W1984152194 creator A5040459018 @default.
• W1984152194 creator A5060684279 @default.
• W1984152194 date "1997-06-01" @default.
• W1984152194 modified "2023-10-15" @default.
• W1984152194 title "Synaptojanin Inhibition of Phospholipase D Activity by Hydrolysis of Phosphatidylinositol 4,5-Bisphosphate" @default.
• W1984152194 cites W1486424890 @default.
• W1984152194 cites W1490646790 @default.
• W1984152194 cites W1543629975 @default.
• W1984152194 cites W1579713959 @default.
• W1984152194 cites W1591103070 @default.
• W1984152194 cites W1596168632 @default.
• W1984152194 cites W1967385667 @default.
• W1984152194 cites W1971997730 @default.
• W1984152194 cites W1975081377 @default.
• W1984152194 cites W1979945257 @default.
• W1984152194 cites W1982304503 @default.
• W1984152194 cites W1986267127 @default.
• W1984152194 cites W1998613940 @default.
• W1984152194 cites W2009093781 @default.
• W1984152194 cites W2016266703 @default.
• W1984152194 cites W2017133620 @default.
• W1984152194 cites W2026039614 @default.
• W1984152194 cites W2031902565 @default.
• W1984152194 cites W2055916570 @default.
• W1984152194 cites W2064983363 @default.
• W1984152194 cites W2079765831 @default.
• W1984152194 cites W2080037386 @default.
• W1984152194 cites W2082426787 @default.
• W1984152194 cites W2085391208 @default.
• W1984152194 cites W2088847457 @default.
• W1984152194 cites W2093160716 @default.
• W1984152194 cites W2133404596 @default.
• W1984152194 cites W2139868649 @default.
• W1984152194 cites W2145120474 @default.
• W1984152194 cites W2160625381 @default.
• W1984152194 cites W59209658 @default.
• W1984152194 doi "https://doi.org/10.1074/jbc.272.25.15980" @default.
• W1984152194 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9188500" @default.
• W1984152194 hasPublicationYear "1997" @default.
• W1984152194 type Work @default.
• W1984152194 sameAs 1984152194 @default.
• W1984152194 citedByCount "115" @default.
• W1984152194 countsByYear W19841521942012 @default.
• W1984152194 countsByYear W19841521942013 @default.
• W1984152194 countsByYear W19841521942014 @default.
• W1984152194 countsByYear W19841521942016 @default.
• W1984152194 countsByYear W19841521942017 @default.
• W1984152194 countsByYear W19841521942018 @default.
• W1984152194 countsByYear W19841521942020 @default.
• W1984152194 countsByYear W19841521942021 @default.
• W1984152194 countsByYear W19841521942023 @default.
• W1984152194 crossrefType "journal-article" @default.
• W1984152194 hasAuthorship W1984152194A5000115883 @default.
• W1984152194 hasAuthorship W1984152194A5006178861 @default.
• W1984152194 hasAuthorship W1984152194A5012014295 @default.
• W1984152194 hasAuthorship W1984152194A5012840606 @default.
• W1984152194 hasAuthorship W1984152194A5020834497 @default.
• W1984152194 hasAuthorship W1984152194A5022011748 @default.
• W1984152194 hasAuthorship W1984152194A5037597705 @default.
• W1984152194 hasAuthorship W1984152194A5040459018 @default.
• W1984152194 hasAuthorship W1984152194A5060684279 @default.
• W1984152194 hasBestOaLocation W19841521941 @default.
• W1984152194 hasConcept C181199279 @default.
• W1984152194 hasConcept C185592680 @default.
• W1984152194 hasConcept C2777853560 @default.
• W1984152194 hasConcept C2778597717 @default.
• W1984152194 hasConcept C2780610907 @default.
• W1984152194 hasConcept C55493867 @default.
• W1984152194 hasConcept C62478195 @default.
• W1984152194 hasConcept C94412978 @default.
• W1984152194 hasConceptScore W1984152194C181199279 @default.
• W1984152194 hasConceptScore W1984152194C185592680 @default.
• W1984152194 hasConceptScore W1984152194C2777853560 @default.
• W1984152194 hasConceptScore W1984152194C2778597717 @default.
• W1984152194 hasConceptScore W1984152194C2780610907 @default.
• W1984152194 hasConceptScore W1984152194C55493867 @default.
• W1984152194 hasConceptScore W1984152194C62478195 @default.
• W1984152194 hasConceptScore W1984152194C94412978 @default.
• W1984152194 hasIssue "25" @default.
• W1984152194 hasLocation W19841521941 @default.
• W1984152194 hasOpenAccess W1984152194 @default.
• W1984152194 hasPrimaryLocation W19841521941 @default.
• W1984152194 hasRelatedWork W2007265956 @default.
• W1984152194 hasRelatedWork W2024372806 @default.
• W1984152194 hasRelatedWork W2040399427 @default.
• W1984152194 hasRelatedWork W2045453514 @default.
• W1984152194 hasRelatedWork W2052082800 @default.
• W1984152194 hasRelatedWork W2071535692 @default.
• W1984152194 hasRelatedWork W2127964122 @default.

• next